Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease

被引：8

作者：

Salim, Sohail Abdul ^{[1
]}

Nair, Lakshmi Ramachandran ^{[2
]}

Thomas, Litty ^{[1
]}

Garla, Vishnu ^{[2
]}

Palabindala, Venkataraman ^{[3
]}

Agarwal, Mohit ^{[1
]}

Fulop, Tibor ^{[4
,5
]}

机构：

[1] Univ Mississippi, Med Ctr, Dept Internal Med, Div Nephrol, Jackson, MS 39216 USA

[2] Univ Mississippi, Med Ctr, Div Endocrinol, Jackson, MS 39216 USA

[3] Univ Mississippi, Med Ctr, Div Hosp Med, Jackson, MS 39216 USA

[4] Univ Debrecen, Fac Med, Dept Med, Div Nephrol, Debrecen, Hungary

[5] Fresenius Med Care, FMC Extracorporeal Life Support Ctr, Esztergom, Hungary

来源：

AMERICAN JOURNAL OF THE MEDICAL SCIENCES | 2018年 / 355卷 / 05期

关键词：

Alkaline phosphatase; End-stage renal disease; Hypercalcemia of malignancy; Parathyroid hormone; RANKL inhibitor; MULTIPLE-MYELOMA; BONE METASTASES; OSTEOPROTEGERIN; CANCER; ACID;

D O I：

10.1016/j.amjms.2017.09.008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Denosumab is a monoclonal antibody directed against the receptor activator of nuclear factor kappa B ligand (RANKL). Denosumab has been shown to reduce the risk of skeletal-related events, including spinal cord compression, pathologic fracture and hypercalcemia of malignancy in patients with bone metastases. Hypocalcemia is a known side effect of denosumab, occurring in an estimated 8-14% of the patients. Here, we present an asymptomatic patient with stage-5 chronic kidney disease and severe hypocalcemia who had received denosumab 1 month earlier.

引用

页码：506 / 509

页数：4

共 50 条

[21] Evaluation of the risk of Denosumab-Associated Hypocalcaemia
Krahenbule, A.
Morel, A.
Aubert, L.
Azzouz, B.
Trenque, T.
DRUG SAFETY, 2017, 40 (10) : 1025 - 1025
[22] Hypocalcemia Post Denosumab in Patients with Chronic Kidney Disease Stage 4-5
Dave, Vatsa
Chiang, Cherie Y.
Booth, Jane
Mount, Peter F.
AMERICAN JOURNAL OF NEPHROLOGY, 2015, 41 (02) : 129 - 137
[23] Denosumab in the treatment of osteoporosis associated with chronic kidney disease
Covic, Adrian
Apetrii, Mugurel
LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (04): : 225 - 227
[24] Denosumab-associated symptomatic hypophosphatemia in normal kidney function: two case reports
Pasquinucci, Ettore
Limardo, Monica
Salerno, Fabio R.
Luise, Carmen M.
Ravasi, Chiara
Vigano, Sara M.
La Milia, Vincenzo
OSTEOPOROSIS INTERNATIONAL, 2024, 35 (12) : 2231 - 2234
[25] Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome
H. Shafqat
K. F. Alquadan
A. J. Olszewski
Osteoporosis International, 2014, 25 : 1187 - 1190
[26] Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome
Shafqat, H.
Alquadan, K. F.
Olszewski, A. J.
OSTEOPOROSIS INTERNATIONAL, 2014, 25 (03) : 1187 - 1190
[27] Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting
Huynh, Andrew Liem Hieu
Baker, Scott Thomas
Stewardson, Andrew James
Johnson, Douglas Forsyth
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (11) : 1274 - 1278
[28] Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis
Yasuda, Yoshinori
Iwama, Shintaro
Arima, Hiroshi
ENDOCRINE JOURNAL, 2019, 66 (03) : 271 - 275
[29] A Rare Reason for Severe Hypocalcemia Following Kidney Transplant: Denosumab Treatment
Aktas, Muride
Unlu, Hayriye Nur Oray
Karatas, Murat
Okut, Gokalp
Eren, Berna
Uslu, Adam
Tatar, Erhan
EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2024, 22 (01) : 342 - 344
[30] A CASE OF SEVERE HYPOCALCEMIA IN THE SETTING OF DENOSUMAB USE AND ACUTE KIDNEY INJURY
Arundel, Cherinne
Logan, Jessica
JOURNAL OF GENERAL INTERNAL MEDICINE, 2018, 33 : S410 - S410

← 1 2 3 4 5 →